Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab

Eculizumab, a humanized monoclonal antibody, is a complement inhibitor indicated for refractory generalized myasthenia gravis (MG). However, there are limited data on the safety of eculizumab for MG during coronavirus disease 2019 (COVID-19) infection. We report a case in which eculizumab was contin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mimori, Masahiro, Komatsu, Teppei, Maku, Takahiro, Mitsumura, Hidetaka, Iguchi, Yasuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Covid-19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975705/
https://www.ncbi.nlm.nih.gov/pubmed/35364770
http://dx.doi.org/10.1007/s10072-022-05922-2
_version_ 1784680423332249600
author Mimori, Masahiro
Komatsu, Teppei
Maku, Takahiro
Mitsumura, Hidetaka
Iguchi, Yasuyuki
author_facet Mimori, Masahiro
Komatsu, Teppei
Maku, Takahiro
Mitsumura, Hidetaka
Iguchi, Yasuyuki
author_sort Mimori, Masahiro
collection PubMed
description Eculizumab, a humanized monoclonal antibody, is a complement inhibitor indicated for refractory generalized myasthenia gravis (MG). However, there are limited data on the safety of eculizumab for MG during coronavirus disease 2019 (COVID-19) infection. We report a case in which eculizumab was continued for MG after contracting COVID-19, followed by a favorable outcome.
format Online
Article
Text
id pubmed-8975705
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-89757052022-04-04 Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab Mimori, Masahiro Komatsu, Teppei Maku, Takahiro Mitsumura, Hidetaka Iguchi, Yasuyuki Neurol Sci Covid-19 Eculizumab, a humanized monoclonal antibody, is a complement inhibitor indicated for refractory generalized myasthenia gravis (MG). However, there are limited data on the safety of eculizumab for MG during coronavirus disease 2019 (COVID-19) infection. We report a case in which eculizumab was continued for MG after contracting COVID-19, followed by a favorable outcome. Springer International Publishing 2022-04-02 2022 /pmc/articles/PMC8975705/ /pubmed/35364770 http://dx.doi.org/10.1007/s10072-022-05922-2 Text en © Fondazione Società Italiana di Neurologia 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Covid-19
Mimori, Masahiro
Komatsu, Teppei
Maku, Takahiro
Mitsumura, Hidetaka
Iguchi, Yasuyuki
Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab
title Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab
title_full Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab
title_fullStr Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab
title_full_unstemmed Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab
title_short Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab
title_sort generalized myasthenia gravis patients infected with covid-19 should continue eculizumab
topic Covid-19
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975705/
https://www.ncbi.nlm.nih.gov/pubmed/35364770
http://dx.doi.org/10.1007/s10072-022-05922-2
work_keys_str_mv AT mimorimasahiro generalizedmyastheniagravispatientsinfectedwithcovid19shouldcontinueeculizumab
AT komatsuteppei generalizedmyastheniagravispatientsinfectedwithcovid19shouldcontinueeculizumab
AT makutakahiro generalizedmyastheniagravispatientsinfectedwithcovid19shouldcontinueeculizumab
AT mitsumurahidetaka generalizedmyastheniagravispatientsinfectedwithcovid19shouldcontinueeculizumab
AT iguchiyasuyuki generalizedmyastheniagravispatientsinfectedwithcovid19shouldcontinueeculizumab

Ejemplares similares